Research progress on PRMTs involved in epigenetic modification and tumour signalling pathway regulation (Review)
- Authors:
- Kailiang Wu
- Chen Niu
- Hanjiao Liu
- Li Fu
-
Affiliations: National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Hexi, Tianjin 300060, P.R. China - Published online on: April 5, 2023 https://doi.org/10.3892/ijo.2023.5510
- Article Number: 62
-
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Vu LD, Gevaert K and De Smet I: Protein language: Post-translational modifications talking to each other. Trends Plant Sci. 23:1068–1080. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jarrold J and Davies CC: PRMTs and arginine methylation: Cancer's best-kept secret? Trends Mol Med. 25:993–1009. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Paik WK and Kim S: Enzymatic methylation of protein fractions from calf thymus nuclei. Biochem Biophys Res Commun. 29:14–20. 1967. View Article : Google Scholar : PubMed/NCBI | |
|
Lin WJ, Gary JD, Yang MC, Clarke S and Herschman HR: The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem. 271:15034–15044. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Blanc RS and Richard S: Arginine methylation: The coming of age. Mol Cell. 65:8–24. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bedford MT and Clarke SG: Protein arginine methylation in mammals: Who, what, and why. Mol Cell. 33:1–13. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hughes RM and Waters ML: Arginine methylation in a beta-hairpin peptide: Implications for Arg-pi interactions, DeltaCp(o), and the cold denatured state. J Am Chem Soc. 128:12735–12742. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Obianyo O, Causey CP, Jones JE and Thompson PR: Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol. 6:1127–1135. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gui S, Wooderchak WL, Daly MP, Porter PJ, Johnson SJ and Hevel JM: Investigation of the molecular origins of protein-arginine methyltransferase I (PRMT1) product specificity reveals a role for two conserved methionine residues. J Biol Chem. 286:29118–29126. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gui S, Gathiaka S, Li J, Qu J, Acevedo O and Hevel JM: A remodeled protein arginine methyltransferase 1 (PRMT1) generates symmetric dimethylarginine. J Biol Chem. 289:9320–9327. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshimoto T, Boehm M, Olive M, Crook MF, San H, Langenickel T and Nabel EG: The arginine methyltransferase PRMT2 binds RB and regulates E2F function. Exp Cell Res. 312:2040–2053. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Frankel A and Clarke S: PRMT3 is a distinct member of the protein arginine N-methyltransferase family. Conferral of substrate specificity by a zinc-finger domain. J Biol Chem. 275:32974–32982. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Shishkova E, Zeng H, Liu F, Kwiecien NW, Hebert AS, Coon JJ and Xu W: Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition. Nat Commun. 8:155712017. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Wang M, Lv Z, Yang N, Liu Y, Bao S, Gong W and Xu RM: Structural insights into protein arginine symmetric dimethylation by PRMT5. Proc Natl Acad Sci USA. 108:20538–20543. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Okuno K, Akiyama Y, Shimada S, Nakagawa M, Tanioka T, Inokuchi M, Yamaoka S, Kojima K and Tanaka S: Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression. Carcinogenesis. 40:15–26. 2019. View Article : Google Scholar | |
|
Hasegawa M, Toma-Fukai S, Kim JD, Fukamizu A and Shimizu T: Protein arginine methyltransferase 7 has a novel homodimer-like structure formed by tandem repeats. FEBS Lett. 588:1942–1948. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, Sayegh J, Daniel J, Clarke S and Bedford MT: PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem. 280:32890–32896. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hadjikyriacou A, Yang Y, Espejo A, Bedford MT and Clarke SG: Unique features of human protein arginine methyltransferase 9 (PRMT9) and its substrate RNA splicing factor SF3B2. J Biol Chem. 290:16723–16743. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fulton MD, Cao M, Ho MC, Zhao X and Zheng YG: The macromolecular complexes of histones affect protein arginine methyltransferase activities. J Biol Chem. 297:1011232021. View Article : Google Scholar : PubMed/NCBI | |
|
Osborne TC, Obianyo O, Zhang X, Cheng X and Thompson PR: Protein arginine methyltransferase 1: Positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. Biochemistry. 46:13370–13381. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Waldmann T, Izzo A, Kamieniarz K, Richter F, Vogler C, Sarg B, Lindner H, Young NL, Mittler G, Garcia BA and Schneider R: Methylation of H2AR29 is a novel repressive PRMT6 target. Epigenetics Chromatin. 4:112011. View Article : Google Scholar : PubMed/NCBI | |
|
Branscombe TL, Frankel A, Lee JH, Cook JR, Yang Z, Pestka S and Clarke S: PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem. 276:32971–32976. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Karkhanis V, Wang L, Tae S, Hu YJ, Imbalzano AN and Sif S: Protein arginine methyltransferase 7 regulates cellular response to DNA damage by methylating promoter histones H2A and H4 of the polymerase δ catalytic subunit gene, POLD1. J Biol Chem. 287:29801–29814. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hu G, Yan C, Xie P, Cao Y, Shao J and Ge J: PRMT2 accelerates tumorigenesis of hepatocellular carcinoma by activating Bcl2 via histone H3R8 methylation. Exp Cell Res. 394:1121522020. View Article : Google Scholar : PubMed/NCBI | |
|
Dong F, Li Q, Yang C, Huo D, Wang X, Ai C, Kong Y, Sun X, Wang W, Zhou Y, et al: PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. Nat Commun. 9:45522018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Lu Y, Espejo A, Wu J, Xu W, Liang S and Bedford MT: TDRD3 is an effector molecule for arginine-methylated histone marks. Mol Cell. 40:1016–1023. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J and Richard S: Cellular pathways influenced by protein arginine methylation: Implications for cancer. Mol Cell. 81:4357–4368. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Fu T, Lv X, Kong Q and Yuan C: A novel SHARPIN-PRMT5-H3R2me1 axis is essential for lung cancer cell invasion. Oncotarget. 8:54809–54820. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang K, Zielinska AE, Shaaban AM, Sanchez-Bailon MP, Jarrold J, Clarke TL, Zhang J, Francis A, Jones LJ, Smith S, et al: PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression. Cell Rep. 21:3498–3513. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cao L, Wu G, Zhu J, Tan Z, Shi D, Wu X, Tang M, Li Z, Hu Y, Zhang S, et al: Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. Nat Commun. 10:37612019. View Article : Google Scholar | |
|
Migliori V, Müller J, Phalke S, Low D, Bezzi M, Mok WC, Sahu SK, Gunaratne J, Capasso P, Bassi C, et al: Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol. 19:136–144. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mitchell LH, Drew AE, Ribich SA, Rioux N, Swinger KK, Jacques SL, Lingaraj T, Boriack-Sjodin PA, Waters NJ, Wigle TJ, et al: Aryl pyrazoles as potent inhibitors of arginine methyltransferases: Identification of the first PRMT6 tool compound. ACS Med Chem Lett. 6:655–659. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Dong S, Zhu R, Hu C, Hou J, Li Y, Zhao Q, Shao X, Bu Q, Li H, et al: Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 6:22799–22811. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Deng X, Shao G, Zhang HT, Li C, Zhang D, Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J and Hu CD: Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene. 36:1223–1231. 2017. View Article : Google Scholar : | |
|
Yao B, Gui T, Zeng X, Deng Y, Wang Z, Wang Y, Yang D, Li Q, Xu P, Hu R, et al: PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome Med. 13:582021. View Article : Google Scholar : PubMed/NCBI | |
|
Kaushik S, Liu F, Veazey KJ, Gao G, Das P, Neves LF, Lin K, Zhong Y, Lu Y, Giuliani V, et al: Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML. Leukemia. 32:499–509. 2018. View Article : Google Scholar | |
|
Yang L, Ma DW, Cao YP, Li DZ, Zhou X, Feng JF and Bao J: PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. Theranostics. 11:3742–3759. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gurung B, Feng Z and Hua X: Menin directly represses Gli1 expression independent of canonical Hedgehog signaling. Mol Cancer Res. 11:1215–1222. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin G, Fan CM, Ng JM, Curran T and Hua X: Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res. 73:2650–2658. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Zhao Y, Zhang J, Lu Y, Liu X, Geng P, Huang B, Zhang Y and Lu J: The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1. Sci Rep. 6:198742016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Lorton B, Gupta V and Shechter D: A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene. 36:373–386. 2017. View Article : Google Scholar | |
|
Liu R, Gao J, Yang Y, Qiu R, Zheng Y, Huang W, Zeng Y, Hou Y, Wang S, Leng S, et al: PHD finger protein 1 (PHF1) is a novel reader for histone H4R3 symmetric dimethylation and coordinates with PRMT5-WDR77/CRL4B complex to promote tumorigenesis. Nucleic Acids Res. 46:6608–6626. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Siarheyeva A, Senisterra G, Allali-Hassani A, Dong A, Dobrovetsky E, Wasney GA, Chau I, Marcellus R, Hajian T, Liu F, et al: An allosteric inhibitor of protein arginine methyltransferase 3. Structure. 20:1425–1435. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jain K and Clarke SG: PRMT7 as a unique member of the protein arginine methyltransferase family: A review. Arch Biochem Biophys. 665:36–45. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P and Sif S: Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 24:9630–9645. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Scaglione A, Patzig J, Liang J, Frawley R, Bok J, Mela A, Yattah C, Zhang J, Teo SX, Zhou T, et al: PRMT5-mediated regulation of developmental myelination. Nat Commun. 9:28402018. View Article : Google Scholar : PubMed/NCBI | |
|
Jing P, Zhao N, Ye M, Zhang Y, Zhang Z, Sun J, Wang Z, Zhang J and Gu Z: Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling. Cancer Lett. 427:38–48. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Karkhanis V, Alinari L, Ozer HG, Chung J, Zhang X, Sif S and Baiocchi RA: Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. J Biol Chem. 295:1165–1180. 2020. View Article : Google Scholar : | |
|
Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, et al: Arginine methylation controls growth regulation by E2F-1. EMBO J. 31:1785–1797. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Zhao X, Zhao L, Li J, Yang H, Zhu Z, Liu J and Huang G: Arginine methylation of SREBP1a via PRMT5 promotes de novo lipogenesis and tumor growth. Cancer Res. 76:1260–1272. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontá L, Durant M, Geng H, Melnick J, Luo Y, et al: PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood. 132:2026–2039. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yu J, Shin B, Park ES, Yang S, Choi S, Kang M and Rho J: Protein arginine methyltransferase 1 regulates herpes simplex virus replication through ICP27 RGG-box methylation. Biochem Biophys Res Commun. 391:322–328. 2010. View Article : Google Scholar | |
|
Fronz K, Güttinger S, Burkert K, Kühn U, Stöhr N, Schierhorn A and Wahle E: Arginine methylation of the nuclear poly(a) binding protein weakens the interaction with its nuclear import receptor, transportin. J Biol Chem. 286:32986–32994. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Katsuno Y, Qin J, Oses-Prieto J, Wang H, Jackson-Weaver O, Zhang T, Lamouille S, Wu J, Burlingame A, Xu J and Derynck R: Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation. J Biol Chem. 293:13059–13072. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Clarke TL, Sanchez-Bailon MP, Chiang K, Reynolds JJ, Herrero-Ruiz J, Bandeiras TM, Matias PM, Maslen SL, Skehel JM, Stewart GS and Davies CC: PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination. Mol Cell. 65:900–916.e7. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hamard PJ, Santiago GE, Liu F, Karl DL, Martinez C, Man N, Mookhtiar AK, Duffort S, Greenblatt S, Verdun RE and Nimer SD: PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. Cell Rep. 24:2643–2657. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hellmuth S, Gutiérrez-Caballero C, Llano E, Pendás AM and Stemmann O: Local activation of mammalian separase in interphase promotes double-strand break repair and prevents oncogenic transformation. EMBO J. 37:e991842018. View Article : Google Scholar : PubMed/NCBI | |
|
Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, et al: GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nat Commun. 9:14182018. View Article : Google Scholar : PubMed/NCBI | |
|
Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, Park PH, Semenova G, Jean S, Cadungog MG, et al: EZH2 inhibition sensitizes CARM1-high, homologous recombination proficient ovarian cancers to PARP inhibition. Cancer Cell. 37:157–167.e6. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wei X, Yang J, Adair SJ, Ozturk H, Kuscu C, Lee KY, Kane WJ, O'Hara PE, Liu D, Demirlenk YM, et al: Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proc Natl Acad Sci USA. 117:28068–28079. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Chitnis N, Nakagawa H, Kita Y, Natsugoe S, Yang Y, Li Z, Wasik M, Klein-Szanto AJ, Rustgi AK and Diehl JA: PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov. 5:288–303. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B and La Thangue NB: Arginine methylation regulates the p53 response. Nat Cell Biol. 10:1431–1439. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB and Menck CFM: DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics (Sao Paulo). 73(Suppl 1): e478s2018. View Article : Google Scholar : PubMed/NCBI | |
|
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, et al: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66:8109–8115. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Peshkin BN, Alabek ML and Isaacs C: BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 32:25–33. 2010. View Article : Google Scholar | |
|
Huang T, Yang Y, Song X, Wan X, Wu B, Sastry N, Horbinski CM, Zeng C, Tiek D, Goenka A, et al: PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Mol Cell. 81:1276–1291.e9. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez-Bailon MP, Choi SY, Dufficy ER, Sharma K, McNee GS, Gunnell E, Chiang K, Sahay D, Maslen S, Stewart GS, et al: Arginine methylation and ubiquitylation crosstalk controls DNA end-resection and homologous recombination repair. Nat Commun. 12:63132021. View Article : Google Scholar : PubMed/NCBI | |
|
Dvinge H, Kim E, Abdel-Wahab O and Bradley RK: RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 16:413–430. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bonnal SC, López-Oreja I and Valcárcel J: Roles and mechanisms of alternative splicing in cancer-implications for care. Nat Rev Clin Oncol. 17:457–474. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fong JY, Pignata L, Goy PA, Kawabata KC, Lee SC, Koh CM, Musiani D, Massignani E, Kotini AG, Penson A, et al: Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 36:194–209.e9. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guccione E and Richard S: The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 20:642–657. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Radzisheuskaya A, Shliaha PV, Grinev V, Lorenzini E, Kovalchuk S, Shlyueva D, Gorshkov V, Hendrickson RC, Jensen ON and Helin K: PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat Struct Mol Biol. 26:999–1012. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Musiani D, Bok J, Massignani E, Wu L, Tabaglio T, Ippolito MR, Cuomo A, Ozbek U, Zorgati H, Ghoshdastider U, et al: Proteomics profiling of arginine methylation defines PRMT5 substrate specificity. Sci Signal. 12:eaat83882019. View Article : Google Scholar : PubMed/NCBI | |
|
Cai T, Cinkornpumin JK, Yu Z, Villarreal OD, Pastor WA and Richard S: Deletion of RBMX RGG/RG motif in Shashi-XLID syndrome leads to aberrant p53 activation and neuronal differentiation defects. Cell Rep. 36:1093372021. View Article : Google Scholar : PubMed/NCBI | |
|
Gerhart SV, Kellner WA, Thompson C, Pappalardi MB, Zhang XP, Montes de Oca R, Penebre E, Duncan K, Boriack-Sjodin A, Le B, et al: Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci Rep. 8:97112018. View Article : Google Scholar : PubMed/NCBI | |
|
AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, et al: Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proc Natl Acad Sci USA. 116:17990–18000. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Roworth AP, Carr SM, Liu G, Barczak W, Miller RL, Munro S, Kanapin A, Samsonova A and La Thangue NB: Arginine methylation expands the regulatory mechanisms and extends the genomic landscape under E2F control. Sci Adv. 5:eaaw46402019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Hadjikyriacou A, Xia Z, Gayatri S, Kim D, Zurita-Lopez C, Kelly R, Guo A, Li W, Clarke SG and Bedford MT: PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145. Nat Commun. 6:64282015. View Article : Google Scholar : PubMed/NCBI | |
|
Suresh S, Huard S, Brisson A, Némati F, Dakroub R, Poulard C, Ye M, Martel E, Reyes C, Silvestre DC, et al: PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer. Cancers (Basel). 14:3062022. View Article : Google Scholar : PubMed/NCBI | |
|
Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, et al: Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 36:100–114.e25. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wei H, Wang B, Miyagi M, She Y, Gopalan B, Huang DB, Ghosh G, Stark GR and Lu T: PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. Proc Natl Acad Sci USA. 110:13516–13521. 2013. View Article : Google Scholar | |
|
Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, Arai H, Tsuruo T and Fujita N: PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res. 7:557–569. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, et al: Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 32:996–1002. 2018. View Article : Google Scholar | |
|
Jiang H, Zhou Z, Jin S, Xu K, Zhang H and Xu J, Sun Q, Wang J and Xu J: PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Sci. 109:1414–1427. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tamiya H, Kim H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, et al: SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. J Clin Invest. 128:517–530. 2018. View Article : Google Scholar : | |
|
Hu Y, Su Y, He Y, Liu W and Xiao B: Arginine methyltransferase PRMT3 promote tumorigenesis through regulating c-MYC stabilization in colorectal cancer. Gene. 791:1457182021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Wang K, Feng X, Wang J, Chu Y, Jia C, He Q and Chen C: PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer. Cell Death Dis. 12:10662021. View Article : Google Scholar | |
|
Abe Y and Tanaka N: Fine-tuning of GLI activity through arginine methylation: its mechanisms and function. Cells. 9:19732020. View Article : Google Scholar : PubMed/NCBI | |
|
Song C, Chen T, He L, Ma N, Li JA, Rong YF, Fang Y, Liu M, Xie D and Lou W: PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. Cell Oncol (Dordr). 43:51–62. 2020. | |
|
Lai Y, Song M, Hakala K, Weintraub ST and Shiio Y: Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res. 10:5175–5182. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu MC, Pan MR, Chu PY, Tsai YL, Tsai CH, Shan YS, Chen LT and Hung WC: Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression. Cancers (Basel). 11:82018. View Article : Google Scholar : PubMed/NCBI | |
|
Gao G, Dhar S and Bedford MT: PRMT5 regulates IRES-dependent translation via methylation of hnRNP A1. Nucleic Acids Res. 45:4359–4369. 2017.PubMed/NCBI | |
|
Plotnikov A, Kozer N, Cohen G, Carvalho S, Duberstein S, Almog O, Solmesky LJ, Shurrush KA, Babaev I, Benjamin S, et al: PRMT1 inhibition induces differentiation of colon cancer cells. Sci Rep. 10:200302020. View Article : Google Scholar : PubMed/NCBI | |
|
Sengupta S, Kennemer A, Patrick K, Tsichlis P and Guerau-de-Arellano M: Protein arginine methyltransferase 5 in T lymphocyte biology. Trends Immunol. 41:918–931. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Kim H, Feng Y, Li Y, Tamiya H, Tocci S and Ronai ZA: PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci Transl Med. 12:eaaz56832020. View Article : Google Scholar : PubMed/NCBI | |
|
Elliott K, Nilsson J and Van den Eynden J: Pharmacologic RNA splicing modulation: A novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response. Signal Transduct Target Ther. 6:3732021. View Article : Google Scholar : PubMed/NCBI | |
|
Nagai Y, Ji MQ, Zhu F, Xiao Y, Tanaka Y, Kambayashi T, Fujimoto S, Goldberg MM, Zhang H, Li B, et al: PRMT5 associates with the FOXP3 homomer and when disabled enhances targeted p185erbB2/neu tumor immunotherapy. Front Immunol. 10:1742019. View Article : Google Scholar | |
|
Kagoya Y, Saijo H, Matsunaga Y, Guo T, Saso K, Anczurowski M, Wang CH, Sugata K, Murata K, Butler MO, et al: Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells. J Autoimmun. 97:10–21. 2019. View Article : Google Scholar | |
|
Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, et al: Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 9:e0018192021. View Article : Google Scholar : PubMed/NCBI | |
|
Schonfeld M, Zhao J, Komatz A, Weinman SA and Tikhanovich I: The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma. J Biol Chem. 295:7126–7137. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar S, Zeng Z, Bagati A, Tay RE, Sanz LA, Hartono SR, Ito Y, Abderazzaq F, Hatchi E, Jiang P, et al: CARM1 inhibition enables immunotherapy of resistant tumors by dual action on tumor cells and T cells. Cancer Discov. 11:2050–2071. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng NN, Zhou M, Sun F, Huai MX, Zhang Y, Qu CY, Shen F and Xu LM: Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World J Gastroenterol. 26:3737–3749. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, Knorr DA, Greenbaum B, Elhanati Y, Hogg SJ, et al: Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 184:4032–4047.e31. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tennant DA, Durán RV and Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 10:267–277. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu MC, Tsai YL, Lin CH, Pan MR, Shan YS, Cheng TY, Cheng SH, Chen LT and Hung WC: Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. J Hematol Oncol. 12:792019. View Article : Google Scholar : PubMed/NCBI | |
|
Bednarz-Misa I, Fortuna P, Fleszar MG, Lewandowski Ł, Diakowska D, Rosińczuk J and Krzystek-Korpacka M: Esophageal squamous cell carcinoma is accompanied by local and systemic changes in L-arginine/NO pathway. Int J Mol Sci. 21:62822020. View Article : Google Scholar : PubMed/NCBI | |
|
Lei Y, Han P, Chen Y, Wang H, Wang S, Wang M, Liu J, Yan W, Tian D and Liu M: Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase A. Clin Transl Med. 12:e6862022. View Article : Google Scholar : PubMed/NCBI | |
|
Hartel NG, Chew B, Qin J, Xu J and Graham NA: Deep protein methylation profiling by combined chemical and immunoaffinity approaches reveals novel PRMT1 targets. Mol Cell Proteomics. 18:2149–2164. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li WJ, He YH, Yang JJ, Hu GS, Lin YA, Ran T, Peng BL, Xie BL, Huang MF, Gao X, et al: Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth. Nat Commun. 12:19462021. View Article : Google Scholar : PubMed/NCBI | |
|
Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, Richard S and Bedford MT: Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem. 283:3006–3010. 2008. View Article : Google Scholar | |
|
Neault M, Mallette FA, Vogel G, Michaud-Levesque J and Richard S: Ablation of PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor suppressor. Nucleic Acids Res. 40:9513–9521. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lorton BM, Harijan RK, Burgos ES, Bonanno JB, Almo SC and Shechter D: A binary arginine methylation switch on histone H3 arginine 2 regulates its interaction with WDR5. Biochemistry. 59:3696–3708. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guccione E, Bassi C, Casadio F, Martinato F, Cesaroni M, Schuchlautz H, Lüscher B and Amati B: Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature. 449:933–937. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dacwag CS, Ohkawa Y, Pal S, Sif S and Imbalzano AN: The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling. Mol Cell Biol. 27:384–394. 2007. View Article : Google Scholar : | |
|
Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, et al: The dual epigenetic role of PRMT5 in acute myeloid leukemia: Gene activation and repression via histone arginine methylation. Leukemia. 30:789–799. 2016. View Article : Google Scholar | |
|
Zhang Z, Nikolai BC, Gates LA, Jung SY, Siwak EB, He B, Rice AP, O'Malley BW and Feng Q: Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency. Nucleic Acids Res. 45:9348–9360. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung N, Fung TK, Zeisig BB, Holmes K, Rane JK, Mowen KA, Finn MG, Lenhard B, Chan LC and So CW: Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4C in acute myeloid leukemia. Cancer Cell. 29:32–48. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Min Z, Xiaomeng L, Zheng L, Yangge D, Xuejiao L, Longwei L, Xiao Z, Yunsong L, Ping Z and Yongsheng Z: Asymmetrical methyltransferase PRMT3 regulates human mesenchymal stem cell osteogenesis via miR-3648. Cell Death Dis. 10:5812019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, van Haren MJ and Martin NI: Peptidic transition state analogues as PRMT inhibitors. Methods. 175:24–29. 2020. View Article : Google Scholar | |
|
Hamey JJ, Rakow S, Bouchard C, Senst JM, Kolb P, Bauer UM, Wilkins MR and Hart-Smith G: Systematic investigation of PRMT6 substrate recognition reveals broad specificity with a preference for an RG motif or basic and bulky residues. FEBS J. 288:5668–5691. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, Cerruti L, Curtis DJ, Patel DJ, Allis CD, et al: PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol. 16:304–311. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jain K, Jin CY and Clarke SG: Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases. Proc Natl Acad Sci USA. 114:10101–10106. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Di Lorenzo A and Bedford MT: Histone arginine methylation. FEBS Lett. 585:2024–2031. 2011. View Article : Google Scholar | |
|
Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Zerayesus S, Zhao X, Zhang W, Pergande MR, Borgia JA, DeGregori J, Port JD, et al: PRMT1 is a novel regulator of epithelial-mesenchymal-transition in non-small cell lung cancer. J Biol Chem. 290:13479–13489. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Rahman MA, Chen ZG and Shin DM: Multiple biological functions of Twist1 in various cancers. Oncotarget. 8:20380–20393. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jobert L, Argentini M and Tora L: PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function. Exp Cell Res. 315:1273–1286. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mizutani S, Yoshida T, Zhao X, Nimer SD, Taniwaki M and Okuda T: Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis. Br J Haematol. 170:859–873. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yamagata K, Daitoku H, Takahashi Y, Namiki K, Hisatake K, Kako K, Mukai H, Kasuya Y and Fukamizu A: Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell. 32:221–231. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu LM, Sun WZ, Fan XZ, Xu YL, Cheng MB and Zhang Y: Methylation of C/EBPα by PRMT1 inhibits its tumor-suppressive function in breast cancer. Cancer Res. 79:2865–2877. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fronz K, Otto S, Kölbel K, Kühn U, Friedrich H, Schierhorn A, Beck-Sickinger AG, Ostareck-Lederer A and Wahle E: Promiscuous modification of the nuclear poly(A)-binding protein by multiple protein-arginine methyltransferases does not affect the aggregation behavior. J Biol Chem. 283:20408–20420. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Boisvert FM, Rhie A, Richard S and Doherty AJ: The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity. Cell Cycle. 4:1834–1841. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Boisvert FM, Déry U, Masson JY and Richard S: Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control. Genes Dev. 19:671–676. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Guendel I, Carpio L, Pedati C, Schwartz A, Teal C, Kashanchi F and Kehn-Hall K: Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function. PLoS One. 5:e113792010. View Article : Google Scholar : PubMed/NCBI | |
|
Huang L, Wang Z, Narayanan N and Yang Y: Arginine methylation of the C-terminus RGG motif promotes TOP3B topoisomerase activity and stress granule localization. Nucleic Acids Res. 46:3061–3074. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Friesen WJ, Paushkin S, Wyce A, Massenet S, Pesiridis GS, Van Duyne G, Rappsilber J, Mann M and Dreyfuss G: The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Mol Cell Biol. 21:8289–8300. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Tran NT, Su H, Wang R, Lu Y, Tang H, Aoyagi S, Guo A, Khodadadi-Jamayran A, Zhou D, et al: Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. Elife. 4:e079382015. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Wang D, Lu J, Huang B, Wang Y, Dong M, Fan D, Li H, Gao Y, Hou P, et al: Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ. 27:3226–3242. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S and Corbo L: Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell. 31:212–221. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nakai K, Xia W, Liao HW, Saito M, Hung MC and Yamaguchi H: The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer. 25:74–80. 2018. View Article : Google Scholar | |
|
Choucair A, Pham TH, Omarjee S, Jacquemetton J, Kassem L, Trédan O, Rambaud J, Marangoni E, Corbo L, Treilleux I and Le Romancer M: The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer. Oncogene. 38:4015–4027. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Jia Z, Xie D, Zhao T, Tan Z, Zhang S, Kong F, Wei D and Xie K: Methylation of HSP70 orchestrates its binding to and stabilization of BCL2 mRNA and renders pancreatic cancer cells resistant to therapeutics. Cancer Res. 80:4500–4513. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chuang CY, Chang CP, Lee YJ, Lin WL, Chang WW, Wu JS, Cheng YW, Lee H and Li C: PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells. Oncol Rep. 38:1115–1123. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou W, Yue H, Li C, Chen H and Yuan Y: Protein arginine methyltransferase 1 promoted the growth and migration of cancer cells in esophageal squamous cell carcinoma. Tumour Biol. 37:2613–2619. 2016. View Article : Google Scholar | |
|
Zhong J, Cao RX, Zu XY, Hong T, Yang J, Liu L, Xiao XH, Ding WJ, Zhao Q, Liu JH and Wen GB: Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. FEBS J. 279:316–335. 2012. View Article : Google Scholar | |
|
Ou CY, LaBonte MJ, Manegold PC, So AY, Ianculescu I, Gerke DS, Yamamoto KR, Ladner RD, Kahn M, Kim JH and Stallcup MR: A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression. Mol Cancer Res. 9:660–670. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D, Theillet C, Vandel L, Bedford MT and Sardet C: Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci USA. 103:13351–13356. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Zhao Z, Meyer MB, Saha S, Yu M, Guo A, Wisinski KB, Huang W, Cai W, Pike JW, et al: CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis. Cancer Cell. 30:179–180. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Feng J, Li L, Lin L, Ji J, Lin C, Liu L, Zhang N, Duan D, Li Z, et al: Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep. 21:e485972020. View Article : Google Scholar | |
|
Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L and Xu W: CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res. 71:2118–2128. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YP, Zhou W, Wang J, Huang X, Zuo Y, Wang TS, Gao X, Xu YY, Zou SW, Liu YB, et al: Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol Cell. 64:673–687. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zakrzewicz D, Didiasova M, Krüger M, Giaimo BD, Borggrefe T, Mieth M, Hocke AC, Zakrzewicz A, Schaefer L, Preissner KT and Wygrecka M: Protein arginine methyltransferase 5 mediates enolase-1 cell surface trafficking in human lung adenocarcinoma cells. Biochim Biophys Acta Mol Basis Dis. 1864:1816–1827. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Ma Y, Hu X, Zheng Y and Chen X: Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth. J Cell Mol Med. 23:1333–1342. 2019. View Article : Google Scholar : | |
|
Rengasamy M, Zhang F, Vashisht A, Song WM, Aguilo F, Sun Y, Li S, Zhang W, Zhang B, Wohlschlegel JA and Walsh MJ: The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. Nucleic Acids Res. 45:11106–11120. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Kong J, Wu Y, Zhang J, Wang T, Li N, Fan J, Wang H, Zhang J and Ling R: PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. Breast Cancer Res Treat. 168:531–542. 2018. View Article : Google Scholar | |
|
Beketova E, Fang S, Owens JL, Liu S, Chen X, Zhang Q, Asberry AM, Deng X, Malola J, Huang J, et al: Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer. Cancer Res. 80:4904–4917. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Yao B, Gui T, Guo C, Wu X, Li J, Ma L, Deng Y, Xu P, Wang Y, et al: PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics. 10:4437–4452. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Zhang J, Liu L, Jiang Y, Ji J, Yan R, Zhu Z and Yu Y: Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer. Biochim Biophys Acta Mol Basis Dis. 1864:2835–2844. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon JY, Lee JS, Park ER, Shen YN, Kim MY, Shin HJ, Joo HY, Cho EH, Moon SM, Shin US, et al: Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells. Oncol Rep. 40:536–544. 2018.PubMed/NCBI | |
|
Jiang H, Zhu Y, Zhou Z and Xu J, Jin S, Xu K, Zhang H, Sun Q, Wang J and Xu J: PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma. Cancer Med. 7:869–882. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chung J, Karkhanis V, Baiocchi RA and Sif S: Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling. J Biol Chem. 294:7692–7710. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, et al: PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia. 33:2898–2911. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hu G, Wang X, Han Y and Wang P: Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis. EXCLI J. 17:1157–1166. 2018. | |
|
Avasarala S, Wu PY, Khan SQ, Yanlin S, Van Scoyk M, Bao J, Di Lorenzo A, David O, Bedford MT, Gupta V, et al: PRMT6 promotes lung tumor progression via the alternate activation of tumor-associated macrophages. Mol Cancer Res. 18:166–178. 2020. View Article : Google Scholar : | |
|
Jiang N, Li QL, Pan W, Li J, Zhang MF, Cao T, Su SG and Shen H: PRMT6 promotes endometrial cancer via AKT/mTOR signaling and indicates poor prognosis. Int J Biochem Cell Biol. 120:1056812020. View Article : Google Scholar | |
|
Baldwin RM, Haghandish N, Daneshmand M, Amin S, Paris G, Falls TJ, Bell JC, Islam S and Côté J: Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget. 6:3013–3032. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng D, He Z, Zheng L, Xie D, Dong S and Zhang P: PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2. Onco Targets Ther. 11:4869–4876. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y and Bedford MT: Protein arginine methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2013. View Article : Google Scholar |
